Inventor · disambiguated record
Ana Z. Gonzalez Buenrostro
Also filed as: GONZALEZ BUENROSTRO ANA · GONZALEZ BUENROSTRO ANA Z · GONZALEZ BUENROSTRO ANA ZURISADAI
19 granted patents·14 pending applications·98 citations·filing 2012–2025
94Inventor score
Top patents by PatentIndex Score
33 records- 0197US11613546B2Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2022·Granted Mar 28, 2023·9 cites·44 claims
- 0297US11548902B1Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical useGILEAD SCIENCES INC·Filed 2021·Granted Jan 10, 2023·7 cites·60 claims
- 0397US11084832B2Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical useGILEAD SCIENCES INC·Filed 2020·Granted Aug 10, 2021·25 cites·47 claims
- 0496US11897892B2Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Feb 13, 2024·6 cites·35 claims
- 0595US12024528B2Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Jul 2, 2024·6 cites·28 claims
- 0693US12187734B2Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Jan 7, 2025·1 cites·27 claims
- 0793US12054496B2Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Aug 6, 2024·2 cites·30 claims
- 0893US11352329B2HIV protease inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted Jun 7, 2022·3 cites·5 claims
- 0991US10100063B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2016·Granted Oct 16, 2018·8 cites·12 claims
- 1088US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 1188US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 1287US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 1386US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 1485US2025188089A1Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1583US10774053B2HIV protease inhibitorsGILEAD SCIENCES INC·Filed 2018·Granted Sep 15, 2020·4 cites·17 claims
- 1683US2025115619A1Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical useGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1782US12227520B2Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical useGILEAD SCIENCES INC·Filed 2022·Granted Feb 18, 2025·0 cites·8 claims
- 1881US11306107B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2017·Granted Apr 19, 2022·2 cites·11 claims
- 1980US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 2075US2025115620A1Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 2174US10836779B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted Nov 17, 2020·0 cites·8 claims
- 2274US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 2369US2025120989A1Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 2469US2025127801A1Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 2568US9758495B2Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Sep 12, 2017·1 cites·37 claims
- 2668US2025122219A1Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 2767US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 2865US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 2964US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 3050US11352371B2Thienopyrimidine derivatives as ACC inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2020·Granted Jun 7, 2022·0 cites·37 claims
- 3150US2025333424A1Antiviral compoundsGILEAD SCIENCES INC·Filed 2025·Application pending·0 cites
- 3244US11274105B2Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonistsAMGEN INC·Filed 2019·Granted Mar 15, 2022·0 cites·15 claims
- 3338US2018036289A1Cobicistat for use in cancer treatmentsGILEAD SCIENCES INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ana Z. Gonzalez Buenrostro files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →